A new study found that intensive antiplatelet therapy with prasugrel reduces ischemic events, including stent thrombosis, compared to standard clopidogrel. The treatment shows promise for patients undergoing percutaneous coronary intervention.
Researchers from NewYork-Presbyterian Hospital/Columbia University Medical Center presented findings on the effectiveness of drug-eluting stents in preventing restenosis. The studies also explored the safety and efficacy of bivalirudin for patients undergoing primary angioplasty, particularly those with diabetes and advanced age.
SourceNew York- Presbyterian Hospital/Columbia University Medical Center·DateMar 29, 2008